Focus:
News
-
3 July 2020
Russia’s RDIF, ChemRar to boost production of Avifavir for Covid-19
A joint venture established by the Russian Direct Investment Fund (RDIF) and ChemRar Group is set to boost production of Avifavir, which secured temporary approval from the Russian government to...
-
3 July 2020
ViiV Healthcare gets FDA approval for HIV therapy Rukobia
ViiV Healthcare has received the US Food and Drug Administration (FDA) approval for Rukobia (fostemsavir) to treat human immunodeficiency virus (HIV)-1 infection in adults with limited treatment options.
-
2 July 2020
Intravacc licences CimCure’s iBoost vaccine technology
Dutch research and development vaccine institute Intravacc has collaborated with cancer immunotherapies developer CimCure to in-licence the latter's iBoost technology for vaccines.
-
2 July 2020
COVID-19 vaccine could be approved and available to public within six months: Poll
The global spread of the COVID-19 pandemic and the resulting economic impact and public health burden has highlighted the urgent need for a vaccine to prevent the disease
-
2 July 2020
Novartis agrees to pay $678m to settle kickback charges in US
Novartis Pharmaceuticals has agreed to pay $678m to settle claims that the company made payments of kickback to doctors who prescribed its medicines, as well as Medicare patients.
-
2 July 2020
Janssen’s Ebola vaccine secures European regulatory approval
Johnson & Johnson unit Janssen Pharmaceutical Companies has received marketing authorisation from the European Commission (EC) for its vaccine regimen designed to prevent Ebola Virus Disease.
-
1 July 2020
Fujifilm signs Avigan licensing deal with Dr Reddy’s and GRA
Japan-based Fujifilm has partnered with Indian pharmaceutical firm Dr. Reddy’s Laboratories and Global Response Aid (GRA) to enable international access to Avigan (favipiravir) as a potential Covid-19 treatment.
-
1 July 2020
FDA offers guidance for Covid-19 vaccine development
The US Food and Drug Administration (FDA) has released guidance with recommendations for the manufacturing, clinical development and approval of a Covid-19 vaccine.
-
1 July 2020
Meissa begins pre-clinical studies of Covid-19 intranasal vaccine
US-based biotechnology company Meissa Vaccines has started preclinical studies and manufacturing of its intranasal, live attenuated vaccine (LAV) candidate against Covid-19.
-
30 June 2020
Takeda forms $900m research alliance with Carmine Therapeutics
Japanese pharmaceutical giant Takeda Pharmaceutical has entered into a research collaboration agreement with US-based Carmine Therapeutics for the discovery, development and commercialisation of new rare disease therapies.